5.45
-1.98%
Close of 9 Nov 2026, in PLN
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Molecure
Its shares trade on GPW under the ticker MOC.WA. It has been listed since 19 April 2018. In the fiscal year to 31 December 2024, it reported revenue of PLN 2.9m and a net loss of PLN 31.3m. At that date it held total assets of PLN 113.7m and shareholders' equity of PLN 103.4m.
Molecure SA engages in the discovery and development of small molecules for the treatment of unmet medical needs. The company is headquartered in Warsaw, Woj. Mazowieckie. The company went IPO on 2018-04-19. The firm is dedicated to discovering, developing and commercializing therapeutics for neoplastic and inflammatory diseases. The firm's business model is focused on drug discovery and development, with its core strength in medicinal chemistry and preclinical biology, enhanced by scientific collaborations in specific disease areas. The firm has a platform of 3 distinct small molecule programs targeting chitinases hydrolytic enzymes with potential utility in diverse inflammatory and fibrotic diseases of high unmet medical need. Additionally, it has initiated a program focused on development of small molecule immune modulators to stop the ability of tumors to escape immune surveillance.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 19 Apr 2018
- Employees
- 109
- Website
- molecure.com ↗
Leadership
Pay as last reported
- Mr. Marcin SzumowskiChairman of the Management Board, Chief Executive OfficerPLN 367,200
- Mr. Slawomir BroniarekFinance Director, Member of the Management BoardPLN 192,000
- Ms. Marta BorkowskaDirector of Operations
- Mr. Adam GolebiowskiVice President Research (Director of Medical Chemistry), Member of the Management Board, since 2022PLN 271,000
- Ms. Karolina DzwonekVice President Biology
- Mr. Jacek OlczakVice President ChemistryPLN 157,500
- Mr. Nicolas BeuzenBusiness Development Director
- Dr. Pawel DobrzanskiSenior Scientific Director, Oncology
- Mr. Slawomir BroniarkaMember of the Management Board
- Mr. Samson FungMember of the Management Board
- Mr. Piotr IwanowskiMember of the Management Board
- Mrs. Agnieszka Rajczuk - SzczepanskaMember of the Management Board
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Molecure SA employs 109 full-time staff in Warsaw.
- The firm focuses on small molecules for unmet medical needs.
- Core strengths include medicinal chemistry and preclinical biology.
Weaknesses
- The company went public on 19 April 2018.
- Operations are limited to the Warsaw region in Poland.
- Only three distinct small molecule programs are currently active.
Opportunities
- Chitinases hydrolytic enzymes target diverse inflammatory and fibrotic diseases.
- Immune modulators aim to stop tumors from escaping surveillance.
- Scientific collaborations enhance development in specific disease areas.
Threats
- Neoplastic and inflammatory diseases present complex therapeutic challenges.
- High unmet medical need implies difficult clinical pathways.
- Small molecule discovery requires significant ongoing research investment.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.